Gastric cancer
Conditions
Interventions
Treatment with docetaxel+Cisplatin+S-1 combination chemotherapy. Docetaxel 50mg/m2 iv (d8), Cisplatin 60mg/m2 iv (d8), S-1 80mg/m2 po (BID) (d1-14)
Sponsors
Tokushima-Hokkaido cancer therapy clinical trial group
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1)Written informed consent. 2)Histologicaly (cytologically) proven gastric cancer. 3)Unresectable gastric cancer. 4)To have measurable lesions. 5)No prior chemotherapy or no influence of prior therapy. 6)Tolerable function of bone marrow, liver and kidney. 7)PS 0 - 1. 8)Expected survival for 3 months. 9)Possible oral intake.
Exclusion criteria
Exclusion criteria: 1)History of hypersensitivity to DCS. 2)Contraindication to TXT, CDDP, S-1, G-CSF. 3)Infectious disease. 4)Severe compliaction. 5)Neuropathy greater than grade 2. 6)Brain metastasis with clinical symptoms. 7)Watery diarea. 8)Active double cancer. 9)Persons to be pregnant or to make pregnant.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Response rate | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival, progression free survival, time to response, duration of response, safety | — |
Countries
Japan
Contacts
Public ContactTetsuji Takayama
Tokushima University Hospital. Department of Gastroenterology
Outcome results
None listed